Indication prioritization and use of Real World Data
In today’s market, there is significant additional value that can be captured by developing an asset for secondary indications or markets. Traditional approaches to indication prioritization cannot be scaled to screen the increasingly segmented disease landscape in a systematic manner. To be effective, an indication prioritization approach must be able to systematically find the most meaningful candidates across thousands of indications – leveraging chemical, biological, clinical, regulatory and commercial data points.
Watch the on-demand webinar to learn more about:
Fill in the form to watch the webinar now.